OOIR: Observatory of International Research

Papers

(The H4-Index of European Respiratory Journal is 63. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension	690
ERS/ATS technical standard on interpretive strategies for routine lung function tests	505
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary	370
ERS statement on chronic thromboembolic pulmonary hypertension	327
Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial	294
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study	292
ERS clinical practice guidelines on treatment of sarcoidosis	289
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes	275
Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19	237
Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study	209
Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry	188
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension	153
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline	150
Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors	150
The impact of COVID-19 on patients with asthma	150
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update	142
Endothelial cells in the pathogenesis of pulmonary arterial hypertension	139
ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure	139
Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation	137
European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years	131
Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life	130
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis	126
E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies	123
European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis	120
Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS	120

Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase	109
Inspiratory muscle training enhances recovery post-COVID-19: a randomised controlled trial	107
Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health	106
European Respiratory Society guidelines for the diagnosis of asthma in adults	105
Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swabversusprofessional-collected nasopharyngeal swab	103
Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences	102
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry	102
Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator	99
European Respiratory Society statement on long COVID follow-up	99
Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up	98
Between inflammation and thrombosis: endothelial cells in COVID-19	96
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial	95
Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study	94
Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation	93
Rothia mucilaginosais an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease	92
Asthma remission: what is it and how can it be achieved?	91
Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study	91
Transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions: a randomised trial	90
Idiopathic pulmonary fibrosis: state of the art for 2023	90
The physiological basis of pulmonary arterial hypertension	89
The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study	84
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry	83
The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)	77
Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors	76
Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis	74
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension	71
Tuberculosis and COVID-19 co-infection: description of the global cohort	71
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	71
Asthma and COVID-19 risk: a systematic review and meta-analysis	70
Progressive pulmonary fibrosis: an expert group consensus statement	68
Interstitial lung disease increases susceptibility to and severity of COVID-19	67
Phenotyping long COVID	67
The high mental health burden of “Long COVID” and its association with on-going physical and respiratory symptoms in all adults discharged from hospital	67
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry	66
Topological data analysis reveals genotype–phenotype relationships in primary ciliary dyskinesia	66
“You can leave your mask on”: effects on cardiopulmonary parameters of different airway protective masks at rest and during maximal exercise	66
Asthma management in low and middle income countries: case for change	65
Metabolomic analyses reveal new stage-specific features of COVID-19	65
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study	63
Comorbid insomnia and sleep apnoea is associated with all-cause mortality	63